Quinn, S. (Susan)

Filtering

20191

Settings

Author search.filters.isAuthorOfPublication.1e0851a9-c13a-4765-97f3-d086cb24a7cc

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
    (Future Medicine Ltd, 2019) Linke, R. (Rolf); Pluzanski, A. (Adam); Wu, Y.L. (Yi-Long); Mok, T.S. (Tony S.); Nakagawa, K. (Kazuhiko); Corral-Jaime, J. (Jesús); Migliorino, M.R. (Maria Rita); Tan, W. (Weiwei); Devgan, G. (Geeta); Quinn, S. (Susan); Wang, T. (Tao); Rosell, R. (Rafael); Lee, K.H. (Ki Hyeong)
    Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement.